Indications
Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
Composition
- Active substance
- rimegepant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vydura
- Active substance
- rimegepant
- ATC code
- N02CD06
- Group
- Nervous system
- Therapeutic area
- Migraine Disorders
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status
- Authorised
- EU authorisation
- 25 Apr 2022